Literature DB >> 29260425

Study of the properties of doxorubicin-resistant cells affected by acute leucosis.

Marina Yu Skorkina1, Elena A Shamray2, Victoria A Salo3, Anatoly S Buchelnikov4, Maxim P Evstigneev3.   

Abstract

The stiffness of cell membrane was found to be one of the factors determining resistance of a cell in vitro to antibiotic doxorubicin action. Membranes of surviving cells are negatively charged (-35 - -30 mV) and have high values of stiffness (2.2-5.1 μРа) at the doxorubicin concentrations in the medium of 1-500 μg/ml. If the drug concentration and exposure time are being increased, only cells with 'soft' membrane (0.25-1 μРа) and positive surface potential (15-29 mV) survive. The data obtained have important prognostic value in studying drug resistance of tumour blood cells and can be used as objective markers of efficiency of the antitumor therapy.

Entities:  

Keywords:  Acute leucosis; Atomic force microscopy; Biomembrane; Doxorubicin; Membrane stiffness; Surface potential

Mesh：

Substances：

Year:  2017        PMID： 29260425     DOI： 10.1007/s10863-017-9738-4

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN： 0145-479X            Impact factor:   2.945


  25 in total

1.  Endocytosis switch controlled by transmembrane osmotic pressure and phospholipid number asymmetry.

Authors:  C Rauch; E Farge
Journal:  Biophys J       Date:  2000-06       Impact factor: 4.033

2.  Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.

Authors:  Yong-Wei Wang; Shuang-Jia Wang; Yi-Nan Zhou; Shang-Ha Pan; Bei Sun
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-24       Impact factor: 4.553

3.  [Estimation of surface potential of lymphocytes from patients with leukemia using Kelvin probe mode].

Authors:  E A Sladkova; M Yu Skorkina
Journal:  Biofizika       Date:  2014 Mar-Apr

4.  Membrane alterations associated with progressive adriamycin resistance.

Authors:  C Wheeler; R Rader; D Kessel
Journal:  Biochem Pharmacol       Date:  1982-08-15       Impact factor: 5.858

5.  3,5-Dimethyl-H-furo[3,2-g]chromen-7-one as a potential anticancer drug by inducing p53-dependent apoptosis in human hepatoma HepG2 cells.

Authors:  Jian-guo Sun; Chao-yue Chen; Ke-wang Luo; Chi-lam Au Yeung; Tsun-yee Tsang; Zhi-zhen Huang; Ping Wu; Kwok-pui Fung; Tim-tak Kwok; Fei-yan Liu
Journal:  Chemotherapy       Date:  2011-03-31       Impact factor: 2.544

6.  In vivo and in vitro sensitization of leukemic cells to adriamycin-induced apoptosis by pentoxifylline. Involvement of caspase cascades and IkappaBalpha phosphorylation.

Authors:  José Manuel Lerma-Díaz; Georgina Hernández-Flores; Jorge R Domínguez-Rodríguez; Pablo C Ortíz-Lazareno; Piedad Gómez-Contreras; Ramón Cervantes-Munguía; Daniel Scott-Algara; Adriana Aguilar-Lemarroy; Luis F Jave-Suárez; Alejandro Bravo-Cuellar
Journal:  Immunol Lett       Date:  2005-11-18       Impact factor: 3.685

7.  Importance of the difference in surface pressures of the cell membrane in doxorubicin resistant cells that do not express Pgp and ABCG2.

Authors:  Charlotte Bell; Claire Hill; Christopher Burton; Adam Blanchard; Freya Shephard; Cyril Rauch
Journal:  Cell Biochem Biophys       Date:  2013-07       Impact factor: 2.194

8.  A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome.

Authors:  Jinbao Liu; Hanqiao Zheng; Mingxin Tang; Youn-Chul Ryu; Xuejun Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-31       Impact factor: 4.733

9.  Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1.

Authors:  Bray Denard; Ching Lee; Jin Ye
Journal:  Elife       Date:  2012-12-18       Impact factor: 8.140

10.  Sensitization of U937 leukemia cells to doxorubicin by the MG132 proteasome inhibitor induces an increase in apoptosis by suppressing NF-kappa B and mitochondrial membrane potential loss.

Authors:  Pablo César Ortiz-Lazareno; Alejandro Bravo-Cuellar; José Manuel Lerma-Díaz; Luis Felipe Jave-Suárez; Adriana Aguilar-Lemarroy; Jorge Ramiro Domínguez-Rodríguez; Oscar González-Ramella; Ruth De Célis; Paulina Gómez-Lomelí; Georgina Hernández-Flores
Journal:  Cancer Cell Int       Date:  2014-02-04       Impact factor: 5.722
View more
  1 in total

1.  Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway.

Authors:  Jie Li; Wenjing Liu; Hongling Hao; Qiuyi Wang; Liying Xue
Journal:  Oncol Lett       Date:  2019-07-09       Impact factor: 2.967
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.